![Cucurbit[8]uril (cucurbit[8]uril; cucurbit[8]uril)](/upload/1124/V64485.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Protein Heterodimerization[1]
The primary targets of cucurbit[8]uril are not traditional biological receptors but rather guest molecules that can be encapsulated within its cavity. It induces heterodimerization of methylviologen (MV) and naphthalene (NP) functionalized proteins. The compound forms stable ternary complexes with MV and NP, enabling selective protein heterodimerization. It can also induce energy transfer between proteins. |
|---|---|
| ln Vitro |
Cucurbit[8]uril (0~20 μM; 48 hours; CHO-K1 cells) causes a slight decrease in relative cell viability, to 86%[2]. Cucurbit[8]uril does, in fact, specifically cause the heterodimerization of MV–eYFP with Np–eCFP. The ternary complex can only form when all three supramolecular components are present because of the high energy transfer that Cucurbit[8]uril induces between the proteins. The methylviologen-induced unspecific protein assembly is inhibited in the presence of Cucurbit[8]uril. Selective protein heterodimers of more hydrophobic proteins can also be successfully formed using the Cucurbit[8]uril ternary system with methylviologen (MV) and naphthalene (NP). For the purpose of preventing MV-induced unspecific dimerization with hydrophobic protein surfaces, Cucurbit[8]uril as a host molecule must be present[1].
In vitro studies demonstrate that cucurbit[8]uril (0-20 μM; 48 hours) in CHO-K1 cells causes relative cell viability to drop marginally to 86%. The compound induces heterodimerization of MV-eYFP with Np-eCFP proteins. In the presence of CB[8], unspecific protein assembly induced by methylviologen is inhibited. The ternary system of CB[8] with MV and NP can be successfully used for the formation of selective protein heterodimers of hydrophobic proteins. |
| ln Vivo |
Studies on mice administered orally also demonstrate the extremely low toxicity of cucurbit[8]uril when administered intravenously in vivo[2].
In vivo studies in mice show that cucurbit[8]uril has very low toxicity following both intravenous injection and oral administration. The compound is orally active as a supramolecular inducer of protein heterodimerization. Its low toxicity profile and oral bioavailability make it a promising candidate for drug delivery applications. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic properties. |
| Enzyme Assay |
Non-cellular assays for cucurbit[8]uril typically involve host-guest chemistry studies using spectroscopic techniques such as UV-Vis, fluorescence, and NMR spectroscopy. These assays measure the binding affinity and stoichiometry of CB[8] with various guest molecules including cations and aromatic substrates. Isothermal titration calorimetry (ITC) is used to determine thermodynamic parameters of inclusion complex formation. These cell-free systems allow for precise characterization of the compound's molecular recognition properties.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: CHO-K1 cells Tested Concentrations: 0~20 μM Incubation Duration: 48 hrs (hours) Experimental Results: At the highest investigated concentration of 20 μM after 48 h, the relative cell viability dropped marginally to 86%. Cellular assays for cucurbit[8]uril are conducted using CHO-K1 cells to assess cytotoxicity. Cells are treated with CB[8] at concentrations up to 20 μM for 48 hours, and cell viability is measured using MTT or similar assays. Protein heterodimerization studies are performed in cells expressing MV- and NP-functionalized fluorescent proteins (e.g., eYFP and eCFP), and energy transfer is measured using FRET or fluorescence microscopy. |
| Animal Protocol |
In vivo animal experiments for cucurbit[8]uril have been conducted in mice to assess toxicity. The compound is administered via intravenous injection or oral gavage, and animals are monitored for signs of toxicity, weight loss, and behavioral changes. Tissue samples may be collected for histopathological examination. These studies have demonstrated that CB[8] has a very low toxicity profile in vivo.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for cucurbit[8]uril are limited but suggest that the compound is orally active. It should be stored at 4°C protected from light and under nitrogen. Stock solutions can be stored below -20°C for several months. The compound is typically shipped at room temperature or with blue ice. Its large molecular size (1329.1 g/mol) and hydrophilicity suggest limited membrane permeability, though oral activity has been demonstrated.
|
| Toxicity/Toxicokinetics |
Toxicological studies show that cucurbit[8]uril has very low toxicity. In CHO-K1 cells, treatment with up to 20 μM for 48 hours results in only a marginal decrease in cell viability to 86%. In vivo studies in mice demonstrate low toxicity following both intravenous injection and oral administration. No significant adverse effects have been reported at the doses tested.
|
| References | |
| Additional Infomation |
Cucurbit[8]uril is a type of cucurbituril.
Other information includes the compound's use in drug delivery, nanozyme catalysis, molecular recognition, and supramolecular assembly. It has a large, highly hydrophobic cavity and can encapsulate cations and aromatic substrates. CB[8] induces heterodimerization of methylviologen and naphthalene functionalized proteins. It has potential applications in targeted drug delivery due to its ability to selectively bind various drug and biomolecule targets with high avidity. |
| Molecular Formula |
C48H48N32O16
|
|---|---|
| Molecular Weight |
1329.10
|
| Exact Mass |
1328.39
|
| CAS # |
259886-51-6
|
| PubChem CID |
16133299
|
| Appearance |
White to off-white solid powder
|
| Density |
2.71
|
| LogP |
-9.1
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
96
|
| Complexity |
2960
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1N2C3C4N(C2=O)CN5C6C7N(C5=O)CN8C9C2N(C8=O)CN5C8C%10N(C5=O)CN5C%11C%12N(C5=O)CN5C%13C%14N(C5=O)CN5C%15C%16N(C5=O)CN5C%17C(N1C5=O)N1CN3C(=O)N4CN6C(=O)N7CN9C(=O)N2CN8C(=O)N%10CN%11C(=O)N%12CN%13C(=O)N%14CN%15C(=O)N%16CN%17C1=O
|
| InChi Key |
CONWISUOKHSUDR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C48H48N32O16/c81-33-49-1-50-18-20-54(34(50)82)4-58-22-24-62(38(58)86)8-66-26-28-70(42(66)90)12-74-30-32-78(46(74)94)15-77-31-29-73(45(77)93)11-69-27-25-65(41(69)89)7-61-23-21-57(37(61)85)3-53(33)19-17(49)51-2-52(18)36(84)56(20)6-60(22)40(88)64(24)10-68(26)44(92)72(28)14-76(30)48(96)80(32)16-79(31)47(95)75(29)13-71(27)43(91)67(25)9-63(23)39(87)59(21)5-55(19)35(51)83/h17-32H,1-16H2
|
| Chemical Name |
3,5,8,10,13,15,18,20,23,25,28,30,33,35,38,40,41,43,45,47,51,53,55,57,59,61,63,65,67,69,71,73-dotriacontazapentacosacyclo[35.3.3.36,7.311,12.316,17.321,22.326,27.331,32.22,41.236,43.13,40.15,8.110,13.115,18.120,23.125,28.130,33.135,38.145,51.147,73.153,55.157,59.161,63.165,67.169,71]octacontane-44,46,48,49,50,52,54,56,58,60,62,64,66,68,70,72-hexadecone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: < 1 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7524 mL | 3.7619 mL | 7.5239 mL | |
| 5 mM | 0.1505 mL | 0.7524 mL | 1.5048 mL | |
| 10 mM | 0.0752 mL | 0.3762 mL | 0.7524 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
